DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Myelofibrosis” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the Myelofibrosis market, comprising
key marketed and pipeline drugs, clinical trials, upcoming and
regulatory events, probability of success, patent information, a 10-year
disease prevalence forecast, and licensing and acquisition deals, as
well as presenting drug-specific revenue forecasts
Key Takeaways
-
The author estimates that in 2017, there were 47,000 prevalent cases
of myelofibrosis in adults aged 50 years and older worldwide, and
forecasts that number to increase to 58,300 prevalent cases by 2026. -
The global prevalence of myelofibrosis is estimated to be 0.0027%.
Incyte’s Jakafi (ruxolitinib phosphate) is the only marketed drug for
myelofibrosis. It is the first FDA-approved oral JAK1/2 inhibitor for
the treatment of the disease. -
The majority of industry-sponsored drugs in active clinical
development for myelofibrosis are in Phase II, with only two drugs in
Phase III. -
Therapies in mid-to-late-stage development for myelofibrosis focus on
a wide variety of targets. The majority of the pipeline drugs are
administered via the oral route. -
High-impact upcoming events for drugs in the myelofibrosis space
comprise topline Phase II trial results and an expected CHMP opinion
for pacritinib. -
The overall likelihood of approval of a Phase I hematologic asset is
10.7%, and the average probability a drug advances from Phase III is
57.6%. Drugs, on average, take 8.7 years from Phase I to approval,
compared to 9.2 years in the overall oncology space. -
There were only three licensing and asset acquisition deals involving
myelofibrosis drugs during 2014-18. The largest deal was the $1,250m
agreement in 2015 between Bristol-Myers Squibb and Promedior, pursuant
to which Bristol-Myers Squibb was granted an exclusive right to
acquire Promedior along with its lead asset PRM-151, which is in
development for idiopathic pulmonary fibrosis and myelofibrosis. -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials for myelofibrosis have been in the early and
mid-phases of development, with 88% of trials in Phase I-II, and only
12% in Phase III-IV. -
The US has a substantial lead in the number of myelofibrosis clinical
trials globally. Germany leads the major EU markets, while Israel has
the top spot in Asia. -
Clinical trial activity in the myelofibrosis space is dominated by
completed trials. Novartis has the highest number of completed
clinical trials for myelofibrosis, with 12 trials. -
Novartis leads industry sponsors with the highest number of clinical
trials for myelofibrosis, followed by Incyte.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
Anemia
Splenomegaly
Curative treatment
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Four Drugs Set For EU Approval, EMA Holds Fire On Pacritinib
Moment Of Truth For Pacritinib And Other EU Approval Hopefuls
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Geron Has Cash, But Does It Have The Imetelstat Data To Push On Without
Janssen?
Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor
Momelotinib
Celgene’s $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And
Beyond
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/cbp7jz
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs , Hematological
Drugs